Immunomodulatory effects of testosterone evaluated in all-trans retinoic acid differentiated HL-60 cells, granulocytes, and monocytes

Boje, Alex; Moesby, Lise; Timm, Michael; Hansen, Erik W.

doi:10.1016/j.intimp.2012.02.008

Cited by 10 publications

(6 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another mechanism by which testosterone limits inflammation is by decreasing the generation of reactive oxygen species generation from differentiated HL-60 cells. Interestingly, the production of reactive oxygen species in response to zymosan, but not LPS, was inhibited by testosterone (228).…”

Section: Cytokine Secretion/reactive Oxygen Species/inflammationmentioning

confidence: 97%

“…This finding is consistent with the idea that the immune system of females produces cytokines in response to pathogens and insults more robustly than that of males. Monocyte or MDM expression of TNF-α, IL-1β, IL-6, and IL-8 is reduced in the presence of testosterone (227)(228)(229). Many studies in this field have relied on human cell lines, such as THP-1 and U937, with or without PMA-induced differentiation into macrophages, and differentiated HL-60 cells, although primary monocytes and MDMs have been used in a few cases (224,230).…”

Section: Cytokine Secretion/reactive Oxygen Species/inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Androgen and Androgen Receptors as Regulators of Monocyte and Macrophage Biology in the Healthy and Diseased Lung

2020

View full text Add to dashboard Cite

Androgens, the predominant male sex hormones, drive the development and maintenance of male characteristics by binding to androgen receptor (AR). As androgens are systemically distributed throughout the whole organism, they affect many tissues and cell types in addition to those in male sexual organs. It is now clear that the immune system is a target of androgen action. In the lungs, many immune cells express ARs and are responsive to androgens. In this review, we describe the effects of androgens and ARs on lung myeloid immune cells-monocytes and macrophages-as they relate to health and disease. In particular, we highlight the effect of androgens on lung diseases, such as asthma, chronic obstructive pulmonary disease and lung fibrosis. We also discuss the therapeutic use of androgens and how circulating androgens correlate with lung disease. In addition to human studies, we also discuss how mouse models have helped to uncover the effect of androgens on monocytes and macrophages in lung disease. Although the role of estrogen and other female hormones has been broadly analyzed in the literature, we focus on the new perspectives of androgens as modulators of the immune system that target myeloid cells during lung inflammation.

show abstract

Section: Cytokine Secretion/reactive Oxygen Species/inflammationmentioning

confidence: 97%

Section: Cytokine Secretion/reactive Oxygen Species/inflammationmentioning

confidence: 99%

Androgen and Androgen Receptors as Regulators of Monocyte and Macrophage Biology in the Healthy and Diseased Lung

2020

View full text Add to dashboard Cite

show abstract

“…The negative physiological sequelae of hypogonadism are also well established, and include bone reabsorption, which can lead to osteoporosis and osteopenia; TTh can normalize bone density (11-13). Multiple studies have also shown that testosterone has important immunomodulatory effects, including regulation of neutrophils and monocytes (14-17). Along with the benefits of TTh, several potential risks have been identified.…”

Section: Introductionmentioning

confidence: 99%

Testosterone therapy and prostate cancer

Pastuszak

Rodríguez

Nguyen

et al. 2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

The use of exogenous testosterone to treat hypogonadism in the men with a history of prostate cancer (CaP) remains controversial due to fears of cancer recurrence or progression. Due to the detrimental impact of hypogonadism on patient quality of life, recent work has examined the safety of testosterone therapy (TTh) in men with a history of CaP. In this review, we evaluate the literature with regards to the safety of TTh in men with a history of CaP. TTh results in improvements in quality of life with little evidence of biochemical recurrence or progression in men with a history of CaP, or de novo cancer in unaffected men. An insufficient amount of evidence is currently available to truly demonstrate the safe use of TTh in men with low risk CaP. In men with high-risk cancer, more limited data suggest that TTh may be safe, but these findings remain inconclusive. Despite the historic avoidance of TTh in men with a history of CaP, the existing body of evidence largely supports the safe and effective use of testosterone in these men, although additional study is needed before unequivocal safety can be demonstrated.

show abstract

“…Neutrophils are the principal effectors as the first step of host defense against injury or infection [ 22 ]. They are recruited to inflammatory sites, where they generate potent destructive enzymes and cytokines and phagocytose potentially injurious stimuli [ 23 , 24 ]. PD-1/PD-L1 pathway participates in inflammatory response and maintains immune homeostasis [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Forsythiaside A prevents zymosan A-induced cell migration in neutrophil-differentiated HL-60 cells via PD-1/PD-L1 pathway

Zhang¹,

Li²,

Xu³

et al. 2023

Heliyon

View full text Add to dashboard Cite

Immunomodulatory effects of testosterone evaluated in all-trans retinoic acid differentiated HL-60 cells, granulocytes, and monocytes

Cited by 10 publications

References 54 publications

Androgen and Androgen Receptors as Regulators of Monocyte and Macrophage Biology in the Healthy and Diseased Lung

Androgen and Androgen Receptors as Regulators of Monocyte and Macrophage Biology in the Healthy and Diseased Lung

Testosterone therapy and prostate cancer

Forsythiaside A prevents zymosan A-induced cell migration in neutrophil-differentiated HL-60 cells via PD-1/PD-L1 pathway

Contact Info

Product

Resources

About